Back to search

National and Kapodistrian University of Athens

Μελέτη και κλινική αξιολόγηση του νέου αποπτωτικού γονιδίου BCL2L12 και της L-DOPA αποκαρβοξυλάσης στον καρκίνο του παχέος εντέρου

Abstract

dc:description

The aim of the present thesis was to study and evaluate clinically the expression of BCL2L12 and DDC genes in colon cancer.For this purpose, a statistically significant sample size of colon tissue specimens from colon cancer patients was collected, mRNA expression analysis of BCL2L12 and DDC genes was carried out with RT-PCR, and a quantitative real-time PCR methodology was developed. After that, DDC protein expression was tested using immunoblotting and enzyme activity was assayed, in colon cancer cell lines and tissues. Furthermore, an effort was made to identify peptides of the classical DDC protein isoform by mass spectrometry, after two-dimensional gel electrophoresis. Finally, mRNA expression analysis of the DDC and BCL2L12 genes, as well as of other apoptosis-related genes, was performed in these colon cancer cell lines, after treatment with chemotherapeutic drugs.High mRNA expression of BCL2L12 and DDC genes was found to be associated with colon tumors of early stage or low grade. BCL2L12 and DDC may be considered as two novel, favorable tissue biomarkers for colon cancer prognosis. Although the DDC enzyme is expressed in both cancerous and non-cancerous colon mucosa, no enzymatic activity concerning the decarboxylation of L-DOPA to dopamine was present in colon. Moreover, it was impossible to identify any peptides originating from DDC by mass spectrometry, even after two-dimensional gel electrophoresis, mainly owing to the very low expression of this protein and to a “masking” phenomenon produced by the presence of other highly abundant proteins, like chaperonins HSP60 and CCT5. Nevertheless, no significant similarity was found between each of these proteins and DDC. Significant modulations of DDC and BCL2L12 at the mRNA level were observed in DLD-1 and Caco-2 cells after treatment with various chemotherapeutic drugs. Remarkable changes in the expression of the other apoptosis-related genes studied, namely BCL2, BAX, BCLX, and FAS, were also noticed in both cell lines.In conclusion, all these modulations of the BCL2L12 and DDC mRNA expression levels in the presence of chemotherapeutic agents, demonstrate that these two genes may be considered as two novel markers for the prediction of an effective therapeutic treatment of colon cancer and for the monitoring of patients’ response to chemotherapy, and may also represent potential targets for molecular cancer therapy.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2009

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Kontos, Christos
  • Κοντός, Χρήστος

Subjects

dc:subject × 20

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/27002

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Kontos, Christos; Κοντός, Χρήστος. Μελέτη και κλινική αξιολόγηση του νέου αποπτωτικού γονιδίου BCL2L12 και της L-DOPA αποκαρβοξυλάσης στον καρκίνο του παχέος εντέρου. National and Kapodistrian University of Athens, 2009. http://hdl.handle.net/10442/hedi/27002